Presentation is loading. Please wait.

Presentation is loading. Please wait.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Published byHilary Brown Modified over 5 years ago

Similar presentations

Presentation on theme: "Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks"— Presentation transcript:

1 Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks
Yuan Yu Michael Huang, MD, Jennifer Shuley Ruth, MD, Sylvia Hsu, MD  Journal of the American Academy of Dermatology  Volume 75, Issue 4, (October 2016) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Patient experienced near-complete clearance of psoriasis lesions until loss of efficacy at 32 weeks into treatment. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Patient had complete clearance of psoriasis lesions until loss of efficacy at 24 weeks into treatment. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Yin-Shuo Chang, MD, Yu-Chen Huang, MD 

Yin-Shuo Chang, MD, Yu-Chen Huang, MD 
Tsung-Yu Tsai, MD, Yu-Chen Huang, MD 

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD 
Facial adenocarcinoma treated with intra-arterial chemotherapy

Facial adenocarcinoma treated with intra-arterial chemotherapy
Volume 3, Issue 6, Pages (November 2017)

Volume 3, Issue 6, Pages (November 2017)
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Psoriasis: Latitude does make a difference

Psoriasis: Latitude does make a difference
Blaschkoid pityriasis rosea

Blaschkoid pityriasis rosea
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Thrombosis-induced ulcerations of the lower legs with coexistent anetoderma due to anti-thrombin III deficiency  Emily R. Clark, PA-C, Joseph C. English 

Thrombosis-induced ulcerations of the lower legs with coexistent anetoderma due to anti-thrombin III deficiency  Emily R. Clark, PA-C, Joseph C. English 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Array of cutaneous adverse effects associated with sorafenib

Array of cutaneous adverse effects associated with sorafenib
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Clindamycin-induced Sweet syndrome

Clindamycin-induced Sweet syndrome

Similar presentations

Ads by Google